International trials for Alzheimer’s disease at PSP with Re:Cognition Health

Multi award-winning company Re:Cognition Health is delighted to announce the recent expansion of one of its key national sites – based at Plymouth Science Park.

The company has four clinics in the UK and has just opened its first clinic in America, with plans for further expansion in both countries during the course of this year.

Recognition Health’s Plymouth Centre offers patients, together with healthy volunteers, the opportunity to enroll into essential international clinical trials.

It means some of the participants will gain early access to new generation medications designed to delay onset and progression of symptoms of Alzheimer’s and related cognitive disorders.

“Alzheimer’s disease is a devastating condition for which there are currently no medications on the market to delay or halt its progression,” says Vicky Eyre, UK Clinical Trial Operations Manager for Re:Cognition Health.

“This is a growing problem for an ageing population and that’s why Re:Cognition Health is working hard to become one of the most effective companies in the world for enrolling individuals into final phase international clinical trials.”

The Plymouth centre, led by Dr Stephen Pearson, opened at Plymouth Science Park in January 2016.

It has expanded this year to accommodate the increasing numbers of volunteers wishing to participate in the many international clinical trials on offer.

The location offers both easy transport links to participants as well as good parking facilities.

“Plymouth Science Park has a large number of tenants whose expertise in science and medicine provide a perfect location for our work in Plymouth."

"It’s an ideal location to build upon world class research and we are delighted to be working towards finding new medications for the treatment and prevention of Alzheimer’s disease.”

“Participants travel to our centre from across the region, from Penzance to Bristol, to have the opportunity to access new medications, which we hope will be available in the future through the NHS,” says Vicky.

“These international clinical studies are designed for individuals aged over 50 with very mild or more advances memory problems. It’s also for cognitively unimpaired volunteers aged 60-85."

"We also offer a screening service for anyone who is concerned about their memory.”

The team is also keen to engage the help of patients and healthy volunteers who might have a family history of Alzheimer’s.

“Research is continuing apace into the causes of Alzheimer’s so that we can better understand this disease and accelerate access for all to disease modifying treatments that one day may lead to prevention,” says Dr Stephen Pearson, Clinical Research Lead at Re:Cognition Health.

“Our trial participants all really value the opportunity to take part in the world class research we are delivering, and to help find treatments for this condition.”